Combination treatment for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests two drugs together for people with cervical cancer that has returned or spread. The goal is to see if the combination can shrink tumors or slow the disease better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have cervical cancer that has come back or spread, and it is a type called squamous, adenocarcinoma, or adenosquamous.
- You have already tried at least one treatment that included platinum (like carboplatin or cisplatin), and the cancer got worse.
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (up and about, not bedridden).
- You have not had certain prior treatments, like EGFR-targeted therapy or T-cell co-stimulatory agents.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug combination for people with advanced cervical cancer that has spread or returned after platinum-based chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a combination of two drugs—relacorilant, which may help chemotherapy work better, and nab-paclitaxel, a type of chemotherapy—for people with cervical cancer that has come back or spread. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs for cervical cancer that has returned or spread after initial treatment. The drugs target cancer cells with a specific marker called HER2 and may help shrink tumors or slow their growth.
This trial tests combining two immunotherapy drugs with chemotherapy and sometimes another drug called bevacizumab, followed by radiation and chemotherapy. It aims to see if this approach can better treat advanced cervical cancer.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
This study tests a new combination of two drugs for cervical cancer that has returned or spread and did not get better with platinum-based chemotherapy. It aims to see if the combination works better than the standard treatment options.
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.